| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Apellis Pharmaceuticals Inc (NASDAQ: APLS)
APLS Technical Analysis
5
| As on 31st Mar 2026 APLS SHARE Price closed @ 40.23 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 24.32 & Strong Buy for SHORT-TERM with Stoploss of 31.31 we also expect STOCK to react on Following IMPORTANT LEVELS. |
APLSSHARE Price
| Open | 40.40 | Change | Price | % |
| High | 40.45 | 1 Day | 23.14 | 135.40 |
| Low | 40.23 | 1 Week | 23.02 | 133.76 |
| Close | 40.23 | 1 Month | 18.66 | 86.51 |
| Volume | 89847985 | 1 Year | 6.30 | 18.57 |
| 52 Week High 40.23 | 52 Week Low 16.36 | ||||
NASDAQ USA Most Active Stocks
| LPTX | 2.05 | 365.91% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| NVDA | 174.40 | 5.59% |
| LMDX | 0.02 | 0.00% |
| YGMZ | 0.02 | -66.67% |
| INTC | 44.13 | 7.14% |
| APLS | 40.23 | 135.40% |
| TIRX | 0.03 | -50.00% |
| LILM | 0.05 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| APLS Daily Charts |
APLS Intraday Charts |
Whats New @ Bazaartrend |
APLS Free Analysis |
|
|
APLS Important Levels Intraday
| RESISTANCE | 40.65 |
| RESISTANCE | 40.52 |
| RESISTANCE | 40.43 |
| RESISTANCE | 40.35 |
| SUPPORT | 40.11 |
| SUPPORT | 40.03 |
| SUPPORT | 39.94 |
| SUPPORT | 39.81 |
APLS Forecast April 2026
| 4th UP Forecast | 56.36 |
| 3rd UP Forecast | 51.19 |
| 2nd UP Forecast | 47.99 |
| 1st UP Forecast | 44.79 |
| 1st DOWN Forecast | 35.67 |
| 2nd DOWN Forecast | 32.47 |
| 3rd DOWN Forecast | 29.27 |
| 4th DOWN Forecast | 24.1 |
APLS Weekly Forecast
| 4th UP Forecast | 46.82 |
| 3rd UP Forecast | 44.71 |
| 2nd UP Forecast | 43.40 |
| 1st UP Forecast | 42.09 |
| 1st DOWN Forecast | 38.37 |
| 2nd DOWN Forecast | 37.06 |
| 3rd DOWN Forecast | 35.75 |
| 4th DOWN Forecast | 33.64 |
APLS Forecast2026
| 4th UP Forecast | 87.15 |
| 3rd UP Forecast | 72.1 |
| 2nd UP Forecast | 62.8 |
| 1st UP Forecast | 53.5 |
| 1st DOWN Forecast | 26.96 |
| 2nd DOWN Forecast | 17.66 |
| 3rd DOWN Forecast | 8.36 |
| 4th DOWN Forecast | -6.69 |
Apellis Pharmaceuticals Inc ( NASDAQ USA Symbol : APLS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
APLS Business Profile
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service